Sumitomo Pharma Drug Patent Portfolio

Sumitomo Pharma owns 2 orange book drugs protected by 13 US patents Given below is the list of Sumitomo Pharma's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11793812 Methods of treating endometriosis 03 May, 2038
Active
US11033551 Methods of treating uterine fibroids 29 Sep, 2037
Active
US11957684 Treatment of heavy menstrual bleeding associated with uterine fibroids 29 Sep, 2037
Active
US10449191 Treatment of prostate cancer 29 Sep, 2037
Active
US10786501 Treatment of prostate cancer 29 Sep, 2037
Active
US11583526 Treatment of prostate cancer 29 Sep, 2037
Active
US12097198 Treatment of prostate cancer 29 Sep, 2037
Active
US10350170 Solid preparation 25 Feb, 2036
Active
US11795178 Compositions of thienopyrimidine derivatives 27 Sep, 2033
Active
US7300935 Thienopyrimidine compounds and use thereof 28 Jan, 2025
Active
US8058280 Substituted thieno[2,3-d]pyrimidin-2,4-dione compounds and uses thereof 28 Jan, 2025
Active
US9346822 Thienopyrimidine compounds and use thereof 17 Feb, 2024 Expired
US8735401 Thienopyrimidine compounds and use thereof 04 Feb, 2024 Expired


Given below is the list of recent legal activities going on the following drug patents of Sumitomo Pharma.

Activity Date Patent Number
Patent litigations
Email Notification 09 Jul, 2024 US10786501
Mail Patent eCofC Notification 09 Jul, 2024 US10786501
Recordation of Patent eCertificate of Correction 09 Jul, 2024 US10786501
Patent eCofC Notification 09 Jul, 2024 US10786501
Mail Certificate of Correction Memo 02 Jul, 2024 US11583526
Mail Certificate of Correction Memo 02 Jul, 2024 US10449191
Post Issue Communication - Certificate of Correction 01 Jul, 2024 US11583526
Post Issue Communication - Certificate of Correction 01 Jul, 2024 US10449191
Certificate of Correction Memo 30 Jun, 2024 US11583526
Certificate of Correction Memo 30 Jun, 2024 US10449191
Post Issue Communication - Certificate of Correction 17 Jun, 2024 US10786501
Mail Certificate of Correction Memo 12 Jun, 2024 US10786501
Certificate of Correction Memo 07 Jun, 2024 US10786501
Email Notification 17 Apr, 2024 US11957684
Recordation of Patent eGrant 16 Apr, 2024 US11957684


Sumitomo Pharma Drug Patents' Oppositions Filed in EPO

Sumitomo Pharma drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Dec 15, 2022, by Sandoz Ag. This opposition was filed on patent number EP17823018A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP17823018A Dec, 2022 SANDOZ AG Granted and Under Opposition


Sumitomo Pharma's Family Patents

Sumitomo Pharma drugs have patent protection in a total of 34 countries. It's US patent count contributes only to 20.2% of its total global patent coverage. Click below to unlock the full patent family tree.

Family Patents



Sumitomo Pharma Drug List

Given below is the complete list of Sumitomo Pharma's drugs and the patents protecting them.


1. Myfembree

Myfembree is protected by 7 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11793812 Methods of treating endometriosis 03 May, 2038
(13 years from now)
Active
US11033551 Methods of treating uterine fibroids 29 Sep, 2037
(12 years from now)
Active
US11957684 Treatment of heavy menstrual bleeding associated with uterine fibroids 29 Sep, 2037
(12 years from now)
Active
US11795178 Compositions of thienopyrimidine derivatives 27 Sep, 2033
(8 years from now)
Active
US7300935 Thienopyrimidine compounds and use thereof 28 Jan, 2025
(a month from now)
Active
US8058280 Substituted thieno[2,3-d]pyrimidin-2,4-dione compounds and uses thereof 28 Jan, 2025
(a month from now)
Active
US9346822 Thienopyrimidine compounds and use thereof 17 Feb, 2024
(9 months ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Myfembree's drug page


2. Orgovyx

Orgovyx is protected by 9 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10449191 Treatment of prostate cancer 29 Sep, 2037
(12 years from now)
Active
US10786501 Treatment of prostate cancer 29 Sep, 2037
(12 years from now)
Active
US11583526 Treatment of prostate cancer 29 Sep, 2037
(12 years from now)
Active
US12097198 Treatment of prostate cancer 29 Sep, 2037
(12 years from now)
Active
US10350170 Solid preparation 25 Feb, 2036
(11 years from now)
Active
US11795178 Compositions of thienopyrimidine derivatives 27 Sep, 2033
(8 years from now)
Active
US7300935 Thienopyrimidine compounds and use thereof 28 Jan, 2025
(a month from now)
Active
US8058280 Substituted thieno[2,3-d]pyrimidin-2,4-dione compounds and uses thereof 28 Jan, 2025
(a month from now)
Active
US8735401 Thienopyrimidine compounds and use thereof 04 Feb, 2024
(10 months ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Orgovyx's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List